# Alun Williams

> Alun Williams is a Series A investor at Parkwalk Advisors backing Software and Health Care. See 17 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Parkwalk Advisors](https://shizune.co/investors/profile/parkwalk-advisors)
- Location: London, United Kingdom
- Total investments: 17
- Last investment: Jun 2025
- Lead investor: 35%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/alun-williams-4595a912/

Alun Williams is a Series A investor at Parkwalk Advisors in London focused on Software and Health Care. Alun Williams joined Parkwalk Advisors as Investment Director in 2014.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Software | 2 | 12% |
| Health Care | 2 | 12% |
| Artificial Intelligence | 2 | 12% |
| Sensor | 1 | 6% |
| Finance | 1 | 6% |

17 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 4 | 24% |
| Seed | 3 | 18% |
| Series B | 1 | 6% |
| Series C | 1 | 6% |
| Series D | 1 | 6% |

8 stages tracked in total.

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Ceryx Medical | Ceryx Medical is developing bioelectronics based on unique, patent protected, chip technology which is able to mimic nerve centres within the body called Central Pattern Generators (CPGs).These CPGs help to control a range of autonomic or rhythmical processes within the body such as peristalsis, heart rate and even walking.It is hoped thatCeryx’s artificial CPGs can restore normal performance where these processes have been affected by disease or injury. | $6.8M | Venture - Series Unknown | Jun 11, 2025 |  |
| Oxford Endovascular | Oxford Endovascular are developing a novel treatment for treating brain aneurysms. The Oxford technology uses a special laser-cut metal alloy which has a shape-memory. It can be posted into a catheter during surgery, inserted into the brain and opened up into a tiny tube mesh (‘flow diverter’) that fits into the natural shape of the blood vessel.This diverts the blood away from the aneurysm, allowing it to heal. | $10.2M | Series A | May 20, 2024 |  |
| Proxisense | Proxisense has developed extreme environment proximity sensors and fluid contamination systems utilising eddy current sensors. The former are finding uses in producing systems which monitor the health of turbine blades in real-time, which can extend component lifetimes and reduce maintenance and downtime costs. Proxisense is targeting the power andaerospace industries for these use cases and is working closely with major OEM players in the fields, including Alstom, Siemens and Rolls-Royce. Contamination of critical fluid systems is a significant issue where transportation assets travel the world and require fuel and lubrication fluids from remote sources. Proxisense’s system can provide real-time, reliable monitoring of these fluids and reduce damage to components, sub-optimal operating conditions and, potentially, system failures. | $1.3M | Series A | Nov 24, 2023 |  |
| TextMine | Textmine is an E2E AI powered knowledge base for your business critical documents (things like invoices, payslips, tender documents, compliance reports and even contracts). We consolidate everything into a single operational layer to enable proactive decision making. We give Increased data transparency, whilst allowing document creation to bemore scalable and uniform. We’ve helped organisations save money and time whilst reducing their risk profile and increasing compliance. | $3.6M | Seed | Mar 14, 2023 |  |
| Ceryx Medical | Ceryx Medical is developing bioelectronics based on unique, patent protected, chip technology which is able to mimic nerve centres within the body called Central Pattern Generators (CPGs).These CPGs help to control a range of autonomic or rhythmical processes within the body such as peristalsis, heart rate and even walking.It is hoped thatCeryx’s artificial CPGs can restore normal performance where these processes have been affected by disease or injury. | $4.8M | Seed | Apr 27, 2022 |  |
| Oxford Endovascular | Oxford Endovascular are developing a novel treatment for treating brain aneurysms. The Oxford technology uses a special laser-cut metal alloy which has a shape-memory. It can be posted into a catheter during surgery, inserted into the brain and opened up into a tiny tube mesh (‘flow diverter’) that fits into the natural shape of the blood vessel.This diverts the blood away from the aneurysm, allowing it to heal. | $9.9M | Series A | Apr 08, 2021 |  |
| TextMine | Textmine is an E2E AI powered knowledge base for your business critical documents (things like invoices, payslips, tender documents, compliance reports and even contracts). We consolidate everything into a single operational layer to enable proactive decision making. We give Increased data transparency, whilst allowing document creation to bemore scalable and uniform. We’ve helped organisations save money and time whilst reducing their risk profile and increasing compliance. | $1.4M | Seed | Mar 11, 2021 |  |
| Mind Foundry | Mind Foundry is an Oxford University Company. Operating at the intersection of innovation and usability, Mind Foundry empowers organisations through the use of Responsible AI built to tackle high-stakes, real-world problems at both individual and population scale. Mind Foundry’s AI Platform and technologies have been used to solve some of the mostchallenging applications of Machine Learning, from insurance fraud detection to complex signal processing, helping customers in insurance, infrastructure, and defence and security tackle the issues that matter most to them whilst promoting the responsible and transparent usage of AI. Founded by pioneers in the field of AI and Machine Learning, Oxford Professors Stephen Roberts and Michael Osborne, the mission of Mind Foundry is to create a future where humans and AI work together to solve the world’s most important problems. | $6.2M | Series A | Jun 26, 2020 |  |
| Arkivum | Arkivum delivers software, services and domain expertise for long term data management and digital preservation globally.We serve organisations around the world in data intensive and regulated markets. We make your long term data secure, accessible and usable for as long as you need it, providing assurance your data is where you need it, when youneed it. Our domain expertise means we can guarantee 100% data integrity and best practice guidance for dealing with new compliance requirements as they are introduced. Our vendor neutral technology and no data lock-in means your data lives where you want it to and you own your data at all times. Arkivum delivers complete confidence in preserving, meeting complex compliance and regulatory requirements and creating business value from your data. Bringing your archived data to life. | $3.9M | Series F | Jan 17, 2020 |  |
| Mind Foundry | Mind Foundry is an Oxford University Company. Operating at the intersection of innovation and usability, Mind Foundry empowers organisations through the use of Responsible AI built to tackle high-stakes, real-world problems at both individual and population scale. Mind Foundry’s AI Platform and technologies have been used to solve some of the mostchallenging applications of Machine Learning, from insurance fraud detection to complex signal processing, helping customers in insurance, infrastructure, and defence and security tackle the issues that matter most to them whilst promoting the responsible and transparent usage of AI. Founded by pioneers in the field of AI and Machine Learning, Oxford Professors Stephen Roberts and Michael Osborne, the mission of Mind Foundry is to create a future where humans and AI work together to solve the world’s most important problems. | $5.9M | Seed | Mar 13, 2019 |  |

10 of 17 investments shown.

## Co-investors
- [IP Group](https://shizune.co/investors/profile/ip-group-plc) — VC Fund, 5 deals together
- [Oxford Capital](https://shizune.co/investors/profile/oxford-capital-partners) — VC Fund, 5 deals together
- [Oxford Science Enterprises](https://shizune.co/investors/profile/oxford-sciences-innovation) — VC Fund, 4 deals together
- [Oxford Science Enterprises](https://shizune.co/investors/profile/oxford-science-enterprises) — VC Fund, 3 deals together
- [Additio Investment Group](https://shizune.co/investors/profile/additio-investment-group) — VC Fund, 2 deals together
- [Business Growth Fund](https://shizune.co/investors/profile/business-growth-fund) — VC Fund, 2 deals together

## About Parkwalk Advisors

VC Fund · London, United Kingdom

Parkwalk is a London-based fund management firm. Parkwalk invests in UK technology companies that have IP backing and freedom to operate, generally spun out of UK universities. Their funds seek to generate capital gains for their investors, enhanced by the attractive tax relief provided by EIS. Parkwalk entered this investment sector in 2009,anticipating a wave of tax-efficient incentives launched by the UK Government to stimulate innovative emerging technology companies and thereby help drive economic growth.Parkwalk utilises academic, technology transfer, venture capital and personal networks developed over many years to gain access to the highest calibre deal-flow. In 2017 Parkwalk joined forces with IP Group plc, a leading intellectual property commercialisation company that is listed on the Main Market of the London Stock Exchange under the ticker symbol IPO. As at March 2019 the combined group has net assets of £1.2bn.

5 contacts available at Parkwalk Advisors.

| Name | Title | Profile |
| --- | --- | --- |
| Alastair Kilgour | Co-Founder and Partner | https://shizune.co/investors/profile/alastair-kilgour |
| Alun Williams | Investment Director | https://shizune.co/investors/profile/alun-williams |
| Chloe Richardson | Investor Relations Manager | https://shizune.co/investors/profile/chloe-richardson |
| Douglas Wright | CEO and Co-Founder | https://shizune.co/investors/profile/moray-wright |
| Enrico D'Angelo | Finance Director | https://shizune.co/investors/profile/enrico-dangelo |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Alun Williams invest in?

Alun Williams invests primarily in Software, Health Care and Artificial Intelligence startups, most often at Series A and Seed stage. Most of the 17 investments tracked by Shizune back companies in United Kingdom. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Alun Williams last invest?

The most recent investment recorded for Alun Williams closed in Jun 2025. Shizune tracks 17 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co